CAR-iNKT cell platform data presented at ASH 2023
Arovella Therapeutics Ltd is pleased to announce its research collaborators from Imperial College London presented data using Arovella’s CAR-iNKT cell therapy platform. Team members from Professor Karadimitris’ lab have presented new data using the CAR-iNKT cell platform in a poster presented at the 65th Annual American Society for Hematology (ASH) conference in San Diego, California. The data released utilises Arovella’s proprietary CAR-iNKT platform, which Professor Karadimitris pioneered.
The poster, presented by Dr Kanagaraju Ponnusamy, describes the use of the platform to produce CAR-iNKT cells targeting B-cell maturation antigen (BCMA) to eliminate Multiple Myeloma and describes the optimisation of the CAR construct. The work identified that the CD28 co-stimulatory domain (shown by the green line in the Kaplan Meier Survival Curve) was more effective than other co-stimulatory domains and led to substantially improved anti-tumour activity in mice. This CD28 co-stimulatory domain is also incorporated into Arovella’s ALA-101 product.
